ArticleMalaria journal2019
Molecular detection of drug resistant malaria in Southern Thailand.
Article in Malaria journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- PvGTSeq and PvCRiSP: Two amplicon-based targeted sequencing panels for Plasmodium vivax.PLoS neglected tropical diseases · 2026Article
- Growth Inhibition and Additive Effect to Antimalarial Drugs ofPathogens (Basel, Switzerland) · 2025Article
- Low Genetic Diversity ofTropical medicine and infectious disease · 2024Article
- Imported malaria into Australia: surveillance insights and opportunities.Journal of travel medicine · 2024Article
- AreBiomedicines · 2024Article
- Surveillance of drug resistance molecular markers in Plasmodium vivax before and after introduction of dihydroartemisinin and piperaquine in Thailand: 2009-2019.Parasitology research · 2023Article
- In Silico and In Vitro Potential of FDA-Approved Drugs for Antimalarial Drug Repurposing againstACS omega · 2023Article
- Community acceptability, participation, and adherence to mass drug administration with primaquine for Plasmodium vivax elimination in Southern Thailand: a mixed methods approach.Malaria journal · 2023Article
- Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication.Tropical diseases, travel medicine and vaccines · 2022Review
- Fighting Plasmodium chloroquine resistance with acetylenic chloroquine analogues.International journal for parasitology. Drugs and drug resistance · 2022Article
- Multidisciplinary Investigations of Sustained Malaria Transmission in the Greater Mekong Subregion.The American journal of tropical medicine and hygiene · 2022Article
- Genetic polymorphisms in genes associated with drug resistance in Plasmodium vivax parasites from northeastern Myanmar.Malaria journal · 2022Article
- Antimalarial Activity of Crude Extract and Solvent Fractions of Leaves ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Novel highly-multiplexed AmpliSeq targeted assay forFrontiers in cellular and infection microbiology · 2022Article
- Hybrid Deep Learning Based on a Heterogeneous Network Profile for Functional Annotations ofInternational journal of molecular sciences · 2021Article
- Plasmodium falciparum phenotypic and genotypic resistance profile during the emergence of Piperaquine resistance in Northeastern Thailand.Scientific reports · 2021Article
- Prediction of Human-Bioinformatics and biology insights · 2021Article
- Molecular Surveillance andFrontiers in cellular and infection microbiology · 2021Article
- An Update on Development of Small-Molecule Plasmodial Kinase Inhibitors.Molecules (Basel, Switzerland) · 2020Review
- Genetic analysis of the orthologous crt and mdr1 genes in Plasmodium malariae from Thailand and Myanmar.Malaria journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug resistance within the major malaria parasites Plasmodium vivax and Plasmodium falciparum threatens malaria control and elimination in Southeast Asia. Plasmodium vivax first-line treatment drug is chloroquine together with primaquine, and the first-line treatment for P. falciparum malaria is artemisinin in combination with a partner drug. Plasmodium vivax and P. falciparum parasites resistant to their respective first-line therapies are now found within Southeast Asia. The resistance perimeters may include high transmission regions of Southern Thailand which are underrepresented in surveillance efforts.
methodsThis study investigated blood samples from malaria centres in Southern Thailand. Genetic loci associated with drug resistance were amplified and sequenced. Drug resistance associated genes Pvmdr1, Pvcrt-o, Pvdhfr, and Pvdhps were characterized for 145 cases of P. vivax malaria, as well as the artemisinin resistance-associated Pfkelch13 gene from 91 cases of P. falciparum malaria.
resultsPlasmodium vivax samples from Southern Thai provinces showed numerous chloroquine and antifolate resistance-associated mutations, including SNP and Pvcrt-o K10-insertion combinations suggestive of chloroquine resistant P. vivax phenotypes. A high proportion of the C580Y coding mutation (conferring artemisinin resistance) was detected in P. falciparum samples originating from Ranong and Yala (where the mutation was previously unreported).
conclusionsThe results demonstrate a risk of chloroquine and antifolate resistant P. vivax phenotypes in Southern Thailand, and artemisinin resistant P. falciparum observed as far south as the Thai-Malaysian border region. Ongoing surveillance of antimalarial drug resistance markers is called for in Southern Thailand to inform case management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.